Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 13Terminated 6Unknown 2Withdrawn 1

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2

Conditions

Lymphoma 5Leukemia, Lymphocytic, Chronic, B-Cell 3Immunoblastic Lymphadenopathy 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Lymphoma, T-Cell 2Lymphoma, Non-Hodgkin 2Lymphoma, Large-Cell, Anaplastic 2Hodgkin Disease 2Sezary Syndrome 1Recurrence 1Neoplasms 1Mycosis Fungoides 1Lymphoma, T-Cell, Peripheral 1Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Extranodal NK-T-Cell 1Leukemia 1Bronchiolitis Obliterans Syndrome 1Anemia, Aplastic 1

Interventions

Cyclophosphamide 12Etoposide 10Doxorubicin 9Brentuximab Vedotin 8fludarabine phosphate 7Vinblastine 7Dacarbazine 7Bleomycin 7Vincristine 6Melphalan 6camrelizumab 5Radiotherapy 5Nivolumab 5Mycophenolic Acid 5Decitabine 5pembrolizumab 4Rituximab 4Peripheral Blood Stem Cell Transplantation 4Gemcitabine 4Filgrastim 4Cytarabine 4Cyclosporine 4Busulfan 4Bendamustine Hydrochloride 4ABVD protocol 4Tacrolimus 3Prednisone 3N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 3Ifosfamide 3Carboplatin 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Unknown × Hodgkin Disease × Alemtuzumab × Clear all
NCT00907036 2013-08-02

Fludarabine Phosphate, Melphalan, and Alemtuzumab Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed Hodgkin Lymphoma

National Cancer Institute (NCI)

Phase 2 Unknown
49 enrolled
Lymphoid

Hodgkin Disease, Lymphoma

NCT00908180 2013-08-02

Carmustine, Etoposide, Cytarabine, Melphalan, and Alemtuzumab Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma

National Cancer Institute (NCI)

Phase 2 Unknown
47 enrolled
Lymphoid

Hodgkin Disease, Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡